RU2758259C2 - Соединение формулы (I), фармацевтическая композиция, применение соединения формулы (I) для лечения гематологических и/или пролиферативных нарушений - Google Patents

Соединение формулы (I), фармацевтическая композиция, применение соединения формулы (I) для лечения гематологических и/или пролиферативных нарушений Download PDF

Info

Publication number
RU2758259C2
RU2758259C2 RU2017127484A RU2017127484A RU2758259C2 RU 2758259 C2 RU2758259 C2 RU 2758259C2 RU 2017127484 A RU2017127484 A RU 2017127484A RU 2017127484 A RU2017127484 A RU 2017127484A RU 2758259 C2 RU2758259 C2 RU 2758259C2
Authority
RU
Russia
Prior art keywords
phenyl
oxazol
ethoxymethyl
pyrazol
methylphenyl
Prior art date
Application number
RU2017127484A
Other languages
English (en)
Russian (ru)
Other versions
RU2017127484A3 (enExample
RU2017127484A (ru
Inventor
Алэн Мюсси
Абделла Бенжахад
Дидье Пез
Франк Сандринелли
Жасон Мартин
Вилли Пикуль
Эммануэль Шевенье
Original Assignee
Аб Сьянс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аб Сьянс filed Critical Аб Сьянс
Publication of RU2017127484A publication Critical patent/RU2017127484A/ru
Publication of RU2017127484A3 publication Critical patent/RU2017127484A3/ru
Application granted granted Critical
Publication of RU2758259C2 publication Critical patent/RU2758259C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2017127484A 2015-02-05 2016-02-05 Соединение формулы (I), фармацевтическая композиция, применение соединения формулы (I) для лечения гематологических и/или пролиферативных нарушений RU2758259C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15154028.3A EP3053920B1 (en) 2015-02-05 2015-02-05 Compounds with anti-tumoral activity
EP15154028.3 2015-02-05
PCT/EP2016/052523 WO2016124747A1 (en) 2015-02-05 2016-02-05 Compounds with anti-tumoral activity

Publications (3)

Publication Number Publication Date
RU2017127484A RU2017127484A (ru) 2019-03-05
RU2017127484A3 RU2017127484A3 (enExample) 2019-08-14
RU2758259C2 true RU2758259C2 (ru) 2021-10-27

Family

ID=52450012

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017127484A RU2758259C2 (ru) 2015-02-05 2016-02-05 Соединение формулы (I), фармацевтическая композиция, применение соединения формулы (I) для лечения гематологических и/или пролиферативных нарушений

Country Status (24)

Country Link
US (1) US10570122B2 (enExample)
EP (2) EP3053920B1 (enExample)
JP (1) JP6713000B2 (enExample)
KR (1) KR102544132B1 (enExample)
CN (1) CN107531685B (enExample)
AR (1) AR103629A1 (enExample)
AU (1) AU2016214283B2 (enExample)
BR (1) BR112017016883B1 (enExample)
CA (1) CA2975644C (enExample)
CY (1) CY1124948T1 (enExample)
DK (1) DK3253749T3 (enExample)
ES (2) ES2796276T3 (enExample)
HR (1) HRP20220114T1 (enExample)
HU (1) HUE059063T2 (enExample)
IL (1) IL253779A0 (enExample)
LT (1) LT3253749T (enExample)
MX (1) MX377742B (enExample)
PL (1) PL3253749T3 (enExample)
PT (1) PT3253749T (enExample)
RS (1) RS62901B1 (enExample)
RU (1) RU2758259C2 (enExample)
TW (1) TWI748938B (enExample)
WO (1) WO2016124747A1 (enExample)
ZA (1) ZA201705537B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018106643A1 (en) * 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
CN109467531A (zh) * 2017-09-08 2019-03-15 沈阳科创化学品有限公司 一种取代吡啶二羧酸衍生物的制备方法
CN112225733B (zh) * 2020-11-25 2022-12-09 湖南科技大学 一种含1,3,4-噻二唑吡啶-2-酮衍生物的制备方法和作为抗癌药物的应用
US12502854B2 (en) 2022-09-27 2025-12-23 Illinois Tool Works Inc. Tire repair system
AU2024225818A1 (en) * 2023-02-24 2025-09-11 Ab Science Compounds for treating myeloid diseases with chromosomal abnormalities
CN117720459A (zh) * 2023-12-26 2024-03-19 江苏希迪制药有限公司 一种阿贝西利中间体5-[(4-乙基哌嗪-1-基)甲基]吡啶-2-胺制备工艺

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033841A1 (en) * 1998-12-07 2000-06-15 Smithkline Beecham Corporation Myt1 kinase inhibitors
WO2004110350A2 (en) * 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
WO2007118903A1 (en) * 2006-04-19 2007-10-25 Janssen Pharmaceutica N.V. Trisubstituted 1,2,4-triazoles
WO2007126957A2 (en) * 2006-03-31 2007-11-08 Novartis Ag New compounds
WO2008103500A1 (en) * 2007-02-22 2008-08-28 Irm Llc Thiazole derivatives as modulators of g protein-coupled receptors
WO2008139161A1 (en) * 2007-05-10 2008-11-20 Sareum Limited Oxazole tyrosine kinase inhibitors
WO2010005841A1 (en) * 2008-07-09 2010-01-14 Merck & Co., Inc. Inhibitors of janus kinases
WO2011001931A1 (ja) * 2009-06-29 2011-01-06 大日本住友製薬株式会社 新規オキサジアゾール誘導体
WO2011006903A1 (en) * 2009-07-15 2011-01-20 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
EA015034B1 (ru) * 2005-09-13 2011-04-29 Янссен Фармацевтика Н.В. 2-анилин-4-арилзамещенные тиазольные производные
WO2012068210A1 (en) * 2010-11-18 2012-05-24 Janssen Pharmaceutica Nv Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
WO2012162461A1 (en) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Phenyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
WO2012166463A2 (en) * 2011-05-27 2012-12-06 Neosome Life Sciences, LLC Aminooxazole inhibitors of cyclin dependent kinases
WO2013014170A1 (en) * 2011-07-27 2013-01-31 Ab Science Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit)

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US810665A (en) * 1905-10-10 1906-01-23 Joseph Mlada Mold for butter.
US1346834A (en) * 1918-08-17 1920-07-20 Charles E Mcmanus Resilient rod
US3740420A (en) 1967-11-28 1973-06-19 Crown Zellerbach Corp Pharmaceutical compositions with dimethyl sulfoxide
US3743727A (en) 1970-11-16 1973-07-03 Crown Zellerbach Corp Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
CA1163561A (en) 1979-11-06 1984-03-13 Cyril Boroda Preparation containing nitroglycerine and optionally other medicaments and preparation thereof
US4460372A (en) 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4411893A (en) 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
CA1236029A (en) 1984-05-14 1988-05-03 Edmund Sandborn Pharmaceutical solutions comprising dimethyl sulfoxide
US4615699A (en) 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
US5906202A (en) 1996-11-21 1999-05-25 Aradigm Corporation Device and method for directing aerosolized mist to a specific area of the respiratory tract
JP4216947B2 (ja) * 1999-05-18 2009-01-28 三井化学株式会社 アミン化合物
MXPA05001277A (es) * 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
US8450302B2 (en) * 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
ATE465731T1 (de) * 2003-10-23 2010-05-15 Ab Science 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
US20090196912A1 (en) 2004-07-30 2009-08-06 Gpc Botech Ag Pyridinylamines
CA2578122A1 (en) * 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
MX2007012392A (es) * 2005-04-04 2007-12-05 Ab Science Derivados de oxazol sustituidos y su uso como inhibidores de tirosina cinasa.
AU2006244203B2 (en) * 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
JP5214096B2 (ja) * 2005-06-17 2013-06-19 富士フイルムファインケミカルズ株式会社 新規なビピリジン誘導体
EP1904065A2 (en) * 2005-07-14 2008-04-02 AB Science Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
GB0524436D0 (en) * 2005-11-30 2006-01-11 Novartis Ag Organic compounds
WO2007131953A1 (en) 2006-05-12 2007-11-22 Ab Science A new process for the synthesis of 2-aminoxazole compounds
FR2901273B1 (fr) * 2006-05-19 2010-12-24 Anaconda Pharma Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant
BRPI0806811A2 (pt) * 2007-01-23 2011-09-13 Palau Pharma Sa derivados de purina
EP2499282B1 (en) * 2009-11-09 2015-04-22 NeuroGenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
CN102812022B (zh) * 2010-01-12 2016-02-03 Ab科学有限公司 噻唑和噁唑激酶抑制剂
GB201012105D0 (en) * 2010-07-19 2010-09-01 Domainex Ltd Novel pyrimidine compounds
EP2616443A1 (en) * 2010-09-14 2013-07-24 Exelixis, Inc. Phtalazine derivatives as jak1 inhibitors
KR101896035B1 (ko) * 2011-08-23 2018-09-07 덕산네오룩스 주식회사 유기전기소자용 신규 화합물, 이를 이용하는 유기전기소자 및 그 단말
CN103436048B (zh) * 2013-08-08 2014-12-03 陕西师范大学 硫脲供体双桥链有机染料及其应用
US20150045353A1 (en) * 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
MX2016012460A (es) * 2014-03-24 2017-05-04 Ab Science Derivados de oxazol sustituidos por diazaespiroalcanona como inhibidores de torosina quinasa de bazo.
EP3144307A1 (en) * 2015-09-18 2017-03-22 AB Science Novel oxazole derivatives that inhibit syk

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033841A1 (en) * 1998-12-07 2000-06-15 Smithkline Beecham Corporation Myt1 kinase inhibitors
WO2004110350A2 (en) * 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
EA015034B1 (ru) * 2005-09-13 2011-04-29 Янссен Фармацевтика Н.В. 2-анилин-4-арилзамещенные тиазольные производные
WO2007126957A2 (en) * 2006-03-31 2007-11-08 Novartis Ag New compounds
WO2007118903A1 (en) * 2006-04-19 2007-10-25 Janssen Pharmaceutica N.V. Trisubstituted 1,2,4-triazoles
WO2008103500A1 (en) * 2007-02-22 2008-08-28 Irm Llc Thiazole derivatives as modulators of g protein-coupled receptors
WO2008139161A1 (en) * 2007-05-10 2008-11-20 Sareum Limited Oxazole tyrosine kinase inhibitors
WO2010005841A1 (en) * 2008-07-09 2010-01-14 Merck & Co., Inc. Inhibitors of janus kinases
WO2011001931A1 (ja) * 2009-06-29 2011-01-06 大日本住友製薬株式会社 新規オキサジアゾール誘導体
WO2011006903A1 (en) * 2009-07-15 2011-01-20 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
WO2012068210A1 (en) * 2010-11-18 2012-05-24 Janssen Pharmaceutica Nv Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
WO2012162461A1 (en) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Phenyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
WO2012166463A2 (en) * 2011-05-27 2012-12-06 Neosome Life Sciences, LLC Aminooxazole inhibitors of cyclin dependent kinases
WO2013014170A1 (en) * 2011-07-27 2013-01-31 Ab Science Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AHLAM MAROUF AL-AZZAWI et al.: "Synthesis and antimicrobial activity of new succinimides bearing different heterocycles", INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY, 2014, vol.4, no.4, pages 755-762. *
JOSHI N.N. et al.: "Synthesis of some substituted pyrazole as possible antimicrobial agents", JOURNAL OF THE INDIOAN CHEMICAL SOCIETY, 1977, vol.54(11), p.1081-3. *
KAMAL M.DAWOOD et al.: "Microwave-Assisted Synthesis of 2-Substituted 4-Biarylyl-1,3-thiazoles by Carbon-Carbon Cross-Coupling in Water", SYNTHESIS, 2010, vol.2010, no.6, p.1030-1038. *
MANE R.A. and INGLE D.B.: "Synthesis of 2-aryl-3-[p-(2`-substituted-aminothiazol-4`-yl)phenyl]-4-thiazolidinones", INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY, 1983, vol.22B(1), p.81-82. *
MANE R.A. and INGLE D.B.: "Synthesis of 2-aryl-3-[p-(2`-substituted-aminothiazol-4`-yl)phenyl]-4-thiazolidinones", INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY, 1983, vol.22B(1), p.81-82. KAMAL M.DAWOOD et al.: "Microwave-Assisted Synthesis of 2-Substituted 4-Biarylyl-1,3-thiazoles by Carbon-Carbon Cross-Coupling in Water", SYNTHESIS, 2010, vol.2010, no.6, p.1030-1038. AHLAM MAROUF AL-AZZAWI et al.: "Synthesis and antimicrobial activity of new succinimides bearing different heterocycles", INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY, 2014, vol.4, no.4, pages 755-762. PRADIP P. DEOHATE et al.: "Synthesis, characterization and antimicrobial study of substituted bis-[1,3,4]-oxadiazole, bis-[1,3,4]-thiadiazole and bis-[1,2,4]-triazole derivatives", JOURNAL OF THE INDIAN CHEMICAL SOCIETY, 2008, vol.85(11), p.1153-1159. JOSHI N.N. et al.: "Synthesis of some substituted pyrazole as possible antimicrobial agents", JOURNAL OF THE INDIOAN *
PRADIP P. DEOHATE et al.: "Synthesis, characterization and antimicrobial study of substituted bis-[1,3,4]-oxadiazole, bis-[1,3,4]-thiadiazole and bis-[1,2,4]-triazole derivatives", JOURNAL OF THE INDIAN CHEMICAL SOCIETY, 2008, vol.85(11), p.1153-1159. *

Also Published As

Publication number Publication date
TWI748938B (zh) 2021-12-11
PT3253749T (pt) 2022-02-03
PL3253749T3 (pl) 2022-03-07
JP2018504415A (ja) 2018-02-15
HRP20220114T1 (hr) 2022-04-15
CN107531685A (zh) 2018-01-02
LT3253749T (lt) 2022-02-25
RU2017127484A3 (enExample) 2019-08-14
DK3253749T3 (da) 2022-02-28
ES2905412T3 (es) 2022-04-08
CA2975644A1 (en) 2016-08-11
US10570122B2 (en) 2020-02-25
CN107531685B (zh) 2021-04-23
EP3053920A1 (en) 2016-08-10
EP3253749B1 (en) 2021-12-08
MX2017010157A (es) 2017-12-18
WO2016124747A1 (en) 2016-08-11
AU2016214283B2 (en) 2020-07-16
US20180079747A1 (en) 2018-03-22
CY1124948T1 (el) 2023-01-05
IL253779A0 (en) 2017-09-28
MX377742B (es) 2025-03-11
ES2796276T3 (es) 2020-11-26
RS62901B1 (sr) 2022-03-31
KR102544132B1 (ko) 2023-06-15
BR112017016883A2 (pt) 2018-03-27
AR103629A1 (es) 2017-05-24
HUE059063T2 (hu) 2022-10-28
KR20170117407A (ko) 2017-10-23
TW201636345A (zh) 2016-10-16
EP3053920B1 (en) 2020-04-08
ZA201705537B (en) 2020-11-25
RU2017127484A (ru) 2019-03-05
JP6713000B2 (ja) 2020-06-24
EP3253749A1 (en) 2017-12-13
BR112017016883B1 (pt) 2023-03-07
AU2016214283A1 (en) 2017-08-10
HK1243700A1 (zh) 2018-07-20
CA2975644C (en) 2025-05-06

Similar Documents

Publication Publication Date Title
CN113214287B (zh) Hpk1抑制剂及其使用方法
JP6355648B2 (ja) Ｗｎｔシグナル伝達経路の３−（ベンゾイミダゾール−２−イル）−インダゾール阻害剤およびそれらの治療的使用
US10105359B2 (en) Tetrahydroisoquinoline derivatives
JP6713000B2 (ja) 抗腫瘍活性を有する化合物
CN105073738A (zh) 作为钠通道调节剂的喹啉及喹唑啉酰胺类
CA2973773C (en) 2-phenyl-3h-imidazo[4,5-b]pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ror1 activity
CA3104521A1 (en) Pikfyve inhibitors
JP2018504415A5 (enExample)
CN105358156A (zh) 双重mek/pi3k抑制剂和使用其的治疗方法
CA2943824A1 (en) Inhibitors of histone demethylases
JP2025529797A (ja) 複素環ｒｂｍ３９モジュレーター
JP7808733B2 (ja) 置換オキソイソインドリニルピペリジン－２，６－ジオン化合物
US20180202388A1 (en) Piston for an internal combustion engine and method for producing the piston for an internal combustion engine
TW202116734A (zh) 乙醯輔酶a合成酶短鏈2(acss2)之小分子抑制劑
CA2943316A1 (en) Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors
HK1225031A (en) Compounds with anti-tumoral activity
HK1225031A1 (en) Compounds with anti-tumoral activity
HK1243700B (en) Compounds with anti-tumoral activity
HK40057478B (en) Hpk1 inhibitors and methods of using same
BR112019022553A2 (pt) novo derivado de tetrahidronaftil ureia
BR112019022553B1 (pt) Compostos ou isômeros ópticos destes ou sais farmaceuticamente aceitáveis destes, e composições farmacêuticas

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20191204

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20200218